

**Statement of Standalone Unaudited Financial Results for the Quarter ended 30.06.2020**

Rs. in lacs

Particulars	Standalone			12 Months
	Quarter Ended			Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from operations</b>				
a Gross Sales/Revenue from Operations	3165.21	2951.75	4523.40	15856.78
b Other Operating Income	0.00	0.00	0.00	0.00
<b>Total Income from operations</b>	<b>3165.21</b>	<b>2951.75</b>	<b>4523.40</b>	<b>15856.78</b>
<b>2 Other Income</b>	<b>78.45</b>	<b>76.04</b>	<b>67.12</b>	<b>252.62</b>
<b>3 Total Income [ 1+2]</b>	<b>3243.66</b>	<b>3027.79</b>	<b>4590.52</b>	<b>16109.40</b>
<b>4 Expenses</b>				
a Cost of materials consumed	440.2	505.01	1173.13	3678.48
b Purchases of stock-in-trade	234.74	343.96	474.83	1815.19
c. Changes in inventories of finished goods, work in progress and Stock in trade	579.69	-66.62	201.11	124.99
e. Employee benefits expenses	1181.98	1014.37	1314.51	5037.42
f. Finance Cost	13.09	14.71	11.77	51.41
g. Depreciation and amortisation expense	27.45	31.70	28.61	112.98
h. Other expenses	463.98	1032.68	1136.10	4347.45
<b>Total expenses</b>	<b>2941.13</b>	<b>2875.81</b>	<b>4340.06</b>	<b>15167.92</b>
<b>5 Profit before exceptional items and taxes (3-4)</b>	<b>302.53</b>	<b>151.98</b>	<b>250.46</b>	<b>941.48</b>
6 Exceptional Items	0.00	0.00	0.00	0.00
<b>7 Profit before tax [5-6]</b>	<b>302.53</b>	<b>151.98</b>	<b>250.46</b>	<b>941.48</b>
8 Tax expense	50.50	-3.50	50.09	154.40
<b>9 Net Profit for the period [7-8]</b>	<b>252.03</b>	<b>155.48</b>	<b>200.37</b>	<b>787.08</b>
10 Other Comprehensive Income				
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
<b>11 Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income [9+11]</b>	<b>252.03</b>	<b>155.48</b>	<b>200.37</b>	<b>787.08</b>
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90
<b>14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)</b>				
a. Basic (Rs.)	0.96	0.59	0.76	3.00
b. Diluted (Rs.)	0.96	0.59	0.76	3.00

Notes

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 29, 2020.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- The revenue for the quarter ended 30-6-2020, is reported net of GST.
- Provision for taxation includes provision for current tax.



Place : New Delhi  
Date : 29-7-2020

By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492